Cargando…

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population

AIM: Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yilong, Han, Shangrong, Qin, Haiqiang, Zheng, Huaguang, Jiang, Bin, Cao, Yong, Gao, Yuan, Guan, Ling, Jia, Qian, Jiang, Yong, Jiao, Yuming, Li, Shuya, Li, Yapeng, Li, Zixiao, Liu, Wei, Ru, Xiaojuan, Sun, Dongling, Sun, Haixin, Wang, Penglian, Wang, Tingting, Zong, Lixia, Guo, Lei, Xie, Xuewei, Xu, Yuming, Xu, Yuyuan, Yang, Xiaomeng, Yang, Yingying, Zhou, Mengyuan, Wang, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548516/
https://www.ncbi.nlm.nih.gov/pubmed/32792457
http://dx.doi.org/10.1136/svn-2020-000385
_version_ 1783592632469946368
author Wang, Yilong
Han, Shangrong
Qin, Haiqiang
Zheng, Huaguang
Jiang, Bin
Cao, Yong
Gao, Yuan
Guan, Ling
Jia, Qian
Jiang, Yong
Jiao, Yuming
Li, Shuya
Li, Yapeng
Li, Zixiao
Liu, Wei
Ru, Xiaojuan
Sun, Dongling
Sun, Haixin
Wang, Penglian
Wang, Tingting
Zong, Lixia
Guo, Lei
Xie, Xuewei
Xu, Yuming
Xu, Yuyuan
Yang, Xiaomeng
Yang, Yingying
Zhou, Mengyuan
Wang, Wenzhi
author_facet Wang, Yilong
Han, Shangrong
Qin, Haiqiang
Zheng, Huaguang
Jiang, Bin
Cao, Yong
Gao, Yuan
Guan, Ling
Jia, Qian
Jiang, Yong
Jiao, Yuming
Li, Shuya
Li, Yapeng
Li, Zixiao
Liu, Wei
Ru, Xiaojuan
Sun, Dongling
Sun, Haixin
Wang, Penglian
Wang, Tingting
Zong, Lixia
Guo, Lei
Xie, Xuewei
Xu, Yuming
Xu, Yuyuan
Yang, Xiaomeng
Yang, Yingying
Zhou, Mengyuan
Wang, Wenzhi
author_sort Wang, Yilong
collection PubMed
description AIM: Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population. METHODS: Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke. RESULTS: This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence. CONCLUSIONS: This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.
format Online
Article
Text
id pubmed-7548516
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75485162020-10-19 Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population Wang, Yilong Han, Shangrong Qin, Haiqiang Zheng, Huaguang Jiang, Bin Cao, Yong Gao, Yuan Guan, Ling Jia, Qian Jiang, Yong Jiao, Yuming Li, Shuya Li, Yapeng Li, Zixiao Liu, Wei Ru, Xiaojuan Sun, Dongling Sun, Haixin Wang, Penglian Wang, Tingting Zong, Lixia Guo, Lei Xie, Xuewei Xu, Yuming Xu, Yuyuan Yang, Xiaomeng Yang, Yingying Zhou, Mengyuan Wang, Wenzhi Stroke Vasc Neurol Guidelines AIM: Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population. METHODS: Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke. RESULTS: This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence. CONCLUSIONS: This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China. BMJ Publishing Group 2020-08-13 /pmc/articles/PMC7548516/ /pubmed/32792457 http://dx.doi.org/10.1136/svn-2020-000385 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Guidelines
Wang, Yilong
Han, Shangrong
Qin, Haiqiang
Zheng, Huaguang
Jiang, Bin
Cao, Yong
Gao, Yuan
Guan, Ling
Jia, Qian
Jiang, Yong
Jiao, Yuming
Li, Shuya
Li, Yapeng
Li, Zixiao
Liu, Wei
Ru, Xiaojuan
Sun, Dongling
Sun, Haixin
Wang, Penglian
Wang, Tingting
Zong, Lixia
Guo, Lei
Xie, Xuewei
Xu, Yuming
Xu, Yuyuan
Yang, Xiaomeng
Yang, Yingying
Zhou, Mengyuan
Wang, Wenzhi
Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title_full Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title_fullStr Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title_full_unstemmed Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title_short Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
title_sort chinese stroke association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548516/
https://www.ncbi.nlm.nih.gov/pubmed/32792457
http://dx.doi.org/10.1136/svn-2020-000385
work_keys_str_mv AT wangyilong chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT hanshangrong chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT qinhaiqiang chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT zhenghuaguang chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT jiangbin chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT caoyong chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT gaoyuan chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT guanling chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT jiaqian chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT jiangyong chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT jiaoyuming chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT lishuya chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT liyapeng chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT lizixiao chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT liuwei chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT ruxiaojuan chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT sundongling chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT sunhaixin chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT wangpenglian chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT wangtingting chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT zonglixia chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT guolei chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT xiexuewei chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT xuyuming chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT xuyuyuan chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT yangxiaomeng chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT yangyingying chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT zhoumengyuan chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT wangwenzhi chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation
AT chinesestrokeassociationguidelinesforclinicalmanagementofcerebrovasculardisordersexecutivesummaryand2019updateofthemanagementofhighriskpopulation